IL37 and graft versus host disease: In other cases, some of these approaches have only recently entered clinical trials for GVHD prophylaxis (e.g., blockade of α4β7 integrin and IL-23 signaling) so the verdict is still out on whether they will be efficacious for prevention of GI tract GVHD.